These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 4614899)
1. Adriamycin (NSC-123127) in combination with cyclophosphamide (NSC-26271): a phase I and II evaluation. Muggia FM; Perloff M; Chia GA; Reed LJ; Escher GC Cancer Chemother Rep; 1974; 58(6):919-26. PubMed ID: 4614899 [No Abstract] [Full Text] [Related]
2. Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer. Ahmann DL; Bisel HF; Eagan RT; Edmonson JH; Hahn RG Cancer Chemother Rep; 1974; 58(6):877-82. PubMed ID: 4614896 [No Abstract] [Full Text] [Related]
3. Combination chemotherapy with methotrexate (NSC-740), adriamycin (NSC-123127), cyclophosphamide (NSC-26271), and 5-fluorouracil (NSC19893) for adult solid tumors. Stephens RL; Hoogstraten B Cancer Chemother Rep; 1974; 58(6):943-5. PubMed ID: 4614901 [No Abstract] [Full Text] [Related]
4. Combination chemotherapy of bronchogenic carcinoma with cyclophosphamide (NSC-26271) and BCNU (NSC-409962). Curtis JE Cancer Chemother Rep; 1974; 58(6):883-8. PubMed ID: 4614897 [No Abstract] [Full Text] [Related]
5. Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer. Eagan RT; Hahn RG; Myers RP Cancer Treat Rep; 1976 Jan; 60(1):115-7. PubMed ID: 1000515 [No Abstract] [Full Text] [Related]
6. Preliminary trials with a combination of adriamycin (NSC-123127) and bleomycin (NSC-125066) in adult malignancies. Tormey DC; Bergevin P; Blom J; Petty W Cancer Chemother Rep; 1973; 57(4):413-8. PubMed ID: 4128422 [No Abstract] [Full Text] [Related]
7. Adriamycin-cyclophosphamide and adriamycin-cis-dichloro-diammineplatinum(II) combination chemotherapy in patients with advanced cancer. Higby DJ; Wilbur D; Wallace HJ; Henderson ES; Weiss R Cancer Treat Rep; 1977 Aug; 61(5):869-73. PubMed ID: 329980 [TBL] [Abstract][Full Text] [Related]
8. High-dose cyclophosphamide (NSC-26271) for the treatment of metastatic testicular neoplasms. Buckner CD; Clift RA; Fefer A; Funk DD; Glucksberg H; Neiman PE; Paulsen A; Storb R; Thomas ED Cancer Chemother Rep; 1974; 58(5 Pt 1):709-14. PubMed ID: 4609599 [No Abstract] [Full Text] [Related]
9. Comparison of adriamycin (NSC-123127) and the combination of 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in advanced prostatic cancer: a preliminary report. Eagan RT; Utz DC; Myers RP; Furlow WL Cancer Chemother Rep; 1975; 59(1):203-7. PubMed ID: 1093666 [TBL] [Abstract][Full Text] [Related]
10. Future implications of phase 2 chemotherapy trials in ninety-five patients with measurable advanced bladder cancer. Yagoda A Cancer Res; 1977 Aug; 37(8 Pt 2):2775-80. PubMed ID: 68814 [No Abstract] [Full Text] [Related]
11. Combination of adriamycin and cyclophosphamide in the treatment of metastatic prostatic carcinoma: a phase II study. Izbicki RM; Amer MH; Al-Sarraf M Cancer Treat Rep; 1979 Jun; 63(6):999-1001. PubMed ID: 380805 [TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with adriamycin (NSC-123127) and 1-(2-chloroethyl)-3-cyclohexyl 1-nitrosourea (CCNU; NSC-79037). Einhorn LH; Livingston RB; Gottlieb JA Cancer Chemother Rep; 1973; 57(4):437-45. PubMed ID: 4586951 [No Abstract] [Full Text] [Related]
13. Response and survival of patients with metastatic neuroblastoma after combination chemotherapy with adriamycin (NSC-123127), cyclophosphamide (NSC-26271), and vincristine (NSC-67574). Gasparini M; Bellani FF; Musumeci R; Bonadonna G Cancer Chemother Rep; 1974; 58(3):365-70. PubMed ID: 4601666 [No Abstract] [Full Text] [Related]
14. Comparison of the therapeutic effects of adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide in the treatment of advanced carcinoma of the cervix. Wallace HJ; Hreshchyshyn MM; Wilbanks GD; Boronow RC; Fowler WC; Blessing JA Cancer Treat Rep; 1978 Oct; 62(10):1435-41. PubMed ID: 709549 [No Abstract] [Full Text] [Related]
15. Effect of nandrolone phenylpropionate (NSC-23162e) on the bone marrow suppression caused by cyclophosphamide (NSC-26271): a clinical trial. Burn JI; Cooke WM Cancer Chemother Rep; 1974; 58(6):867-70. PubMed ID: 4615786 [No Abstract] [Full Text] [Related]
16. Combination chemotherapy with adriamycin (NSC-123127) and cyclophosphamide (NSC-26271) for solid tumors: a phase II trial. Lloyd RE; Jones SE; Salmon SE; Durie BG; McMahon LJ Cancer Treat Rep; 1976 Jan; 60(1):77-83. PubMed ID: 1000520 [TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial. Chlebowski RT; Hestorff R; Sardoff L; Weiner J; Bateman JR Cancer; 1978 Dec; 42(6):2546-52. PubMed ID: 365313 [TBL] [Abstract][Full Text] [Related]
18. Treatment of metastatic breast cancer with adriamycin-cyclophosphamide induction followed by alternating combination therapy. Abeloff MD; Ettinger DS Cancer Treat Rep; 1977 Dec; 61(9):1685-9. PubMed ID: 340033 [TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy with adriamycin and cyclophosphamide (with or without radiation therapy) for carcinoma of the lung. Herman TS; Jones SE; McMahon LJ; Lloyd RE; Heusinkveld RS; Miller RC; Salmon SE Cancer Treat Rep; 1977 Aug; 61(5):875-9. PubMed ID: 196753 [No Abstract] [Full Text] [Related] [Next] [New Search]